GlaxoSmithKline (NYSE:GSK) isn’t the only big drug company overhauling how pharmaceutical sales representatives talk to doctors. Others are now adapting with new sales practices.GlaxoSmithKline last year made waves when it implemented a new sales model that rewarded sales representatives for their knowledge of GSK drugs and their ability to communicate that knowledge to physicians. The [...]

Eli Lilly is withdrawing Xigris from markets worldwide after a major study showed the drug doesn’t work for sepsis.I thought it would be a good time to rerun my post from earlier this year about conflict of interest problems with Xigris:An Archives of Internal Medicine article (Conflicts of Interest in Cardiovascular Clinical Practice Guidelines) [...]

Current medical news and unique business news for anyone who cares about the healthcare industry.Amylin Pharmaceuticals 1, Eli Lilly 0 – A California courtissued a temporary restraining order against Eli Lilly relating to Amylin Pharmaceuticals’ lawsuit regarding Amylin’s diabetes collaboration agreement with Lilly. The temporary restraining order prevents Lilly from selling another rival drug that [...]

Two Northfield, Minnesota veterinarians, Mike Strobel and Mark Werner, are in the process of raising $5 million for their two-year-old Aurora Pharmaceutical as they seek to develop niche veterinary medicine products that will allow them compete with big pharmaceutical companies.

The U.S. Constitution’s Commerce Clause states that Congress has the power to “regulate Commerce ’ among the several States.” To supporters of health reform, the Commerce Clause is the Grinch that stole Obamacare, writes the Health Care Blog. To opponents, it might seem like a Sanity Clause.

How did our nation’s most ambitious experiment in universal healthcare — comprehensive Medicare coverage for every kidney failure patient — descend from a “supremely hopeful moment” nearly four decades ago to a $20-billion-a-year “hulking monster” that kills thousands of patients? ProPublica asks in its latest investigative series.

Indianapolis drug maker Eli Lilly & Co. (NYSE:LLY) has agreed to pay up to $800 million for Avid Radiopharmaceuticals, the Philadelphia developer of a tracing agent that can help diagnose Alzheimer’s disease. The tracing agent, florbetapir F 18 — which last week topped the Cleveland Clinic’s Top 10 Medical Innovations list for 2011 — is coupled with a PET scan to allow doctors to see inside patients’ brains to detect beta-amyloid plaques, the tell-tale signature of Alzheimer’s.

Virtually every House Democrat from a swing district who took a gamble by voting for the health law ended up losing on Tuesday, according to the New York Times.

What if you eliminated or really whacked co-pays for drugs that could make a difference in people’s health? As postage-meter maker Pitney Bowes found out, more people take their medicines, reports NPR.

Defunding by Congress and implementation by governors are the two major threats facing healthcare reform, Tom Daschle, former U.S. Senate majority leader who almost became Department of Health and Human Services nomination in the Obama administration, tells Kaiser Health News.